Application Notes

Cellastim S – Reconstitution Application Note

rHSA Reconstitution Video Protocol

AAV Production – How To Improve Transfection Efficiency and Titer Yield

Exbumin – Reconstitution Application Note

Exbumin – Stabilizing Virus with Albumin to Improve Yield Application Note

Expansion of Adherent HEK293T Cells in Flasks in Chemically Defined Cell Culture Media

Lentrivirus Production Protocol in Serum-Free Conditions – How To Improve Transfection Efficiency and Titer Yield

OptiPEAK T Lymphocyte XPR Expansion of T Cells without Serum in Chemically Defined Media

OptiVERO – Formulation of a blood-free and chemically defined virus production media for VERO cells

OptiVERO – Virus Production Using VERO Cells in Flasks without Serum in Chemically Defined Cell Culture Media Application Note

OptiVERO – Virus Production Using VERO Cells with Microcarriers Without Serum in Chemically Defined Cell Culture Media

Recombinant Human Leukemia Inhibitory Factor for the Enhanced Expansion of Neural Stem Cells

Reducing Serum-Associated Contaminants from Growth Media in Primary Cell Culture

Transient Transfection Protocol – Enhancement of Transfection Efficiency Using Recombinant Transferrin with Serum-Free HEK293 Media

Use of Gas Permeable Rapid Expansion (G-Rex®) Culture ware with Chemically Defined Media for Simplistic and Robust T Lymphocyte Expansion

Using Recombinant Transferrin in the Expansion of Hematopoietic Stem Cells Application Note

Blog

3 Takeaways from the World Vaccine Congress 2018

ASGCT 2019: Remarkable Milestones and Achievements in Cell and Gene Therapy

BIO 2018: The Emergence of Gene & Cell Therapy

BIO Europe 2018: From Lab Innovations to Commercial Realities

BioInnovation on Parade: Philly Stands Proud for BIO 2019!

Controlling Impurities in Cell Culture Media

ECI Conference 2019: The Latest Innovations and Trends in Cell & Gene Therapy

Explore the Latest Developments in T-reg Research and Clinical Application

Exploring the Latest Research and Opportunities in T-reg Therapy

Happy Holidays from the InVitria Team!

High-Performance Production of Viral Vectors for Cell and Gene Therapy Using OptiPEAK HEK293t Complete Media

Improvement of Vaccine Manufacturing Process with Use of Recombinant HSA Excipient

InVitria at the American Association of Immunologists 2018 Conference

InVitria Expands European and UK Footprint

InVitria Expands Operations to Anschutz Medical Campus in the Denver Metro Area

InVitria’s Top Insights from ISCT 2018 – Montreal

Join InVitria at ECI 2019

Join InVitria at Phacilitate 2019

Phacilitate 2019 and World Stem Cell Summit

Recombinant Albumin for Stabilization of Live-Attenuated Viral Vaccines

Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease

SARS-CoV2 and Influenza – Double Threat

Solving the Vaccine Supply Challenge

The Emergence of Serum-Free Cell Culture Media – Blood-Free Chemically Defined Components

Universal Vaccine Against Seasonal Influenza Steps Closer to Reality with the Results of FluGen Phase 2 Clinical Trial

Interviews

Blood-Free Fetal Bovine Serum Alternatives in Cell Culture Media

Revolutionizing Cell Immunotherapies with Serum Free T Cell Media

Journal Articles (DOI Links)

Utilization of Recombinant Albumins in the Expansion of Human T Lymphocytes

Accurate nanoelectrode recording of human pluripotent cell-derived cardiomyocytes for assaying drugs and modeling disease

Formulation and production of a blood-free and chemically defined virus production media for VERO cells

Improvements in Viral Vector Manufacturing Process with Chemical Definition of Cell Culture Media & Excipients

Posters

Adherent HEK293t Cells Cultured in Pall’s iCELLis® Bioreactor with OptiPEAK HEK293t Blood-Free Chemically Defined Media Exhibit Robust and Rapid Population Doubling Times

Cellastim S – Optimizing Antibody Production in Animal-Free Media with the Supplementation of Recombinant Human Albumin

Chemically Defined iCELLis® Bioreactor-Based Lentiviral Vector Mass Production

Chemically Defined iCELLis® Bioreactor-Based Viral Vector Manufacturing – Application of Aber Biomass Probes to Inform Transfection Timing

Improving Vaccine Development, Performance, and Stability with Recombinant HSA Excipient

Product Brochures

2021 Product Catalog

2020 Product Catalog

ITSE AF – Brochure

Lysobac – Brochure – E.Coli Lysis

Optiferrin – Product Brochure

Product Specifications

ITS – Specifications

OptiPEAK HEK293t – Product Specifications

SDS

Exbumin – Safety Data Sheet

ITSE AF – Safety Data Sheet

Lysobac – Safety Data Sheet

Lysosure – Safety Data Sheet

Optibumin – Safety Data Sheet

OptiPEAK HEK293t – Safety Data Sheet

Cellastim S – Safety Data Sheet

Use Guidelines

Cellastim S – Guidelines for Use

Exbumin – Guidelines for Use

ITS – Guidelines for Use

ITSE AF – Guidelines for Use

ITSE+A – Guidelines for Use

Lysobac – Guidelines for Use

Optiferrin – Guidelines for Use

OptiVERO – Guidelines for Use

Webinar

Accelerating Vaccine Development Through Use of Blood-Free Components

White Papers

Cellastim S – Recombinant Human Serum Albumin in the Generation of Functional Cardiomyocytes from Pluripotent Stem Cells

Emergence of Blood-Free Recombinant Human Albumin

Formulation and production of a blood‐free and chemically defined virus production media for VERO cells

Optiferrin – Recombinant Transferrin an Iron Transport Protein in Cell Culture Media

Process Optimization for Lentivirus Production in the iCELLis® Nano Using a Chemically Defined, Animal Component Free HEK293 Media